Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ABIVAX Report Publication Announcement 2021

Sep 30, 2021

1063_rns_2021-09-30_c3d47620-2e84-4a92-92e6-1752758bd682.html

Report Publication Announcement

Open in viewer

Opens in your device viewer

News Details

Corporate | 30 September 2021 18:00

Abivax announces the release of its 2021 half-year financial report

DGAP-News: ABIVAX / Key word(s): Half Year Report

30.09.2021 / 18:00

The issuer is solely responsible for the content of this announcement.

Abivax announces the release of its 2021 half-year financial report

PARIS, France, September 30, 2021 – 6:00 pm (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX), a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, today announces the publication of its 2021 half-year financial report. This document is available in electronic version on the website of the company ( www.abivax.com – “Investors” ) and on the website of the French financial markets authority, AMF ( www.amf-france.org ).

*****

About Abivax (www.abivax.com)

Abivax, a clinical stage biotechnology company, is developing novel therapies that modulate the physiological inflammation and immunological pathways to treat patients with chronic inflammatory diseases, viral infections, and cancer. Abivax is listed on Euronext compartment B (ISIN: FR0012333284 – Mnémo: ABVX). Based in Paris and Montpellier, Abivax has two drug candidates in clinical development, ABX464 to treat severe chronic inflammatory diseases, and ABX196 to treat hepatocellular carcinoma. More information on the company is available at www.abivax.com . Follow us on Twitter @ABIVAX_.

Contacts

Abivax

Communications

Regina Jehle

[email protected]

+33 6 24 50 69 63
Investors

LifeSci Advisors

Ligia Vela-Reid

[email protected]

+44 7413 825310
Press Relations & Investors Europe

MC Services AG

Anne Hennecke

[email protected]

+49 211 529 252 22
Public Relations France

Actifin

Ghislaine Gasparetto

[email protected]

+33 6 21 10 49 24
Public Relations France

DGM Conseil

Thomas Roborel de Climens

[email protected]

+33 6 14 50 15 84
Public Relations USA

Rooney Partners LLC

Jeanene Timberlake

[email protected]

+1 646 770 8858

30.09.2021 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.

The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

Archive at www.dgap.de


show this